Searching semaglutide on Google Scholar: how to read the research and what it means for you

The decision most people face: trusting trial data they can't fully parse

A question our prescribers hear most weeks is some version of: "I've read studies online but I don't know which ones to believe." That's a reasonable place to land. Google Scholar surfaces everything from industry-sponsored phase 3 trials to small mechanistic studies to opinion pieces, and the results look very different depending on which you're reading. The decision isn't really "does semaglutide work", the large randomised trials settle that. The real decision is whether this medicine, based on the weight and quality of that evidence, makes sense as part of your own treatment plan.

The trial most clinicians and regulators cite as the foundation is STEP 1, published in the New England Journal of Medicine (2032183). It recruited 1,961 adults with obesity or overweight plus a weight-related condition, randomised them to either 2.4mg semaglutide weekly or placebo, and followed them for 68 weeks. The semaglutide group lost an average of around 15% of body weight; the placebo group around 2.4%. NICE reviewed this and related studies when it recommended semaglutide (Wegovy) for NHS use under technology appraisal TA875. That appraisal is publicly available and is a useful, plain-English starting point if you want to understand how UK regulators weighed the evidence.

When you use Google Scholar, filtering by publication year and sorting by citation count helps surface the trials that have been most scrutinised by other researchers. A highly cited, peer-reviewed trial in a major journal carries more interpretive weight than a conference abstract or a preprint that hasn't yet been through peer review.

What the semaglutide literature does and doesn't cover

The published STEP programme is large and covers a range of populations: people with obesity and no diabetes (STEP 1), people with type 2 diabetes (STEP 2), maintenance after initial loss (STEP 4), and a cardiovascular outcomes study. That breadth is part of why MHRA licensing extended beyond pure weight loss. More recently, a new indication for MASH, a form of fatty liver disease, received conditional approval in July 2026, and those trial data are now entering journals too.

What the literature covers less thoroughly is long-term weight maintenance after stopping treatment, real-world adherence rates, and outcomes in populations who were underrepresented in the trials. Google Scholar searches on "semaglutide discontinuation" or "semaglutide regain" will find emerging evidence on these questions, but the data are newer and sparser than the core weight-loss trials. If you want a plain-language summary of what the research currently shows, the NHS medicines page on semaglutide distills the clinical picture without requiring you to interpret statistics yourself.

It's also worth noting that Ozempic, which also contains semaglutide, appears throughout the Google Scholar literature, but in a diabetes, not a weight-loss, context. The two licences are distinct, and the doses differ. Searching specifically for "semaglutide 2.4mg weight management" will filter results toward the Wegovy evidence base, and if you want to understand how the dose escalation works at the semaglutide 2mg stage, that detail is worth reviewing alongside the trial summaries. For a broader look at how effective semaglutide actually is in practice, our clinical overview breaks this down without the statistical noise.

Reading funding sources and study design when you search

One practical issue with searching any pharmaceutical topic on Google Scholar is that a large proportion of the primary trial literature is funded by the manufacturer, in this case Novo Nordisk. That doesn't make the findings wrong. Regulatory agencies like the MHRA and NICE assess these trials rigorously and are independent of manufacturers. But it is worth applying basic critical appraisal: who funded it, how large was the sample, was there a randomised control group, and were dropouts reported transparently?

Systematic reviews and meta-analyses, which pool data from multiple studies, tend to give a more balanced picture than any single trial. The Cochrane Library publishes meta-analyses on GLP-1 medicines, and the NIHR Evidence database offers plain-English summaries of NHS-relevant research. When you search on semaglutide's mechanism and pharmacology, pairing a Google Scholar result with its NICE appraisal or an NHS summary gives you independent verification alongside the original data.

If you've worked through the literature and want to understand what dose schedule looks like in practice, the information on starting semaglutide at the lowest dose explains the titration rationale in clinical terms, though the actual titration for any individual is always decided by their prescriber based on response and tolerability. Cost is also a factor many people weigh when reviewing their options; the cost context for Wegovy in the UK covers what private pricing typically includes and why headline figures vary between providers.

What comes next if you've decided the evidence is convincing

Finding the trial data persuasive is one thing. Establishing whether Wegovy is clinically appropriate for you is another, and that step requires an actual assessment. The licensed eligibility criteria in the UK are based on BMI (broadly, 30 or above, or 27 or above with a qualifying weight-related condition) but the prescriber reviews your full picture, not just a number. Contraindications, current medicines, and your history all feed into that clinical judgment.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it arrives. If approved, treatment is dispatched the same day for free next-working-day delivery. There are no subscription arrangements and no automatic renewals; every repeat order goes through a fresh clinical review. You can verify our pharmacy on the GPhC register (premises number 9012878), that link takes you directly to our listing. If you've done the research and want a clinical view on whether Wegovy fits your situation, the right next step is starting your free consultation with our prescribers.